COVID-19 Therapy: What Weapons Do We Bring into Battle?

Overview

Journal Bioorg Med Chem

Specialties Biochemistry
Chemistry

Date 2020 Sep 29

PMID 32992245

Citations 17

Authors

Sinara Monica Vitalino de Almeida

Jose Cleberson Santos Soares

Keriolaine Lima Dos Santos

Josival Emanuel Ferreira Alves

Amelia Galdino Ribeiro

Iris Trindade Tenorio Jacob

Cindy Juliane da Silva Ferreira

Jessica Celerino Dos Santos

Jamerson Ferreira de Oliveira

Luiz Bezerra de Carvalho Junior

Maria do Carmo Alves de Lima

Affiliations

Soon will be listed here.

Abstract

Urgent treatments, in any modality, to fight SARS-CoV-2 infections are desired by society in general, by health professionals, by Estate-leaders and, mainly, by the scientific community, because one thing is certain amidst the numerous uncertainties regarding COVID-19: knowledge is the means to discover or to produce an effective treatment against this global disease. Scientists from several areas in the world are still committed to this mission, as shown by the accelerated scientific production in the first half of 2020 with over 25,000 published articles related to the new coronavirus. Three great lines of publications related to COVID-19 were identified for building this article: The first refers to knowledge production concerning the virus and pathophysiology of COVID-19; the second regards efforts to produce vaccines against SARS-CoV-2 at a speed without precedent in the history of science; the third comprehends the attempts to find a marketed drug that can be used to treat COVID-19 by drug repurposing. In this review, the drugs that have been repurposed so far are grouped according to their chemical class. Their structures will be presented to provide better understanding of their structural similarities and possible correlations with mechanisms of actions. This can help identifying anti-SARS-CoV-2 promising therapeutic agents.

Citing Articles

Outcomes comparison between the first and the subsequent SARS-CoV-2 waves - a systematic review and meta-analysis.

Caldonazo T, Treml R, Vianna F, Tasoudis P, Kirov H, Mukharyamov M Multidiscip Respir Med. 2023; 18(1):933.

PMID: 38155706 PMC: 10690722. DOI: 10.4081/mrm.2023.933.

Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients.

Hegazy S, Tharwat S, Hassan A World J Clin Cases. 2023; 11(26):6105-6121.

PMID: 37731581 PMC: 10507553. DOI: 10.12998/wjcc.v11.i26.6105.

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients.

Hegazy S, Tharwat S, Hassan A Open Med (Wars). 2023; 18(1):20230768.

PMID: 37588660 PMC: 10426270. DOI: 10.1515/med-2023-0768.

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients.

Hegazy S, Tharwat S, Hassan A J Clin Virol Plus. 2023; 3(2):100151.

PMID: 37220480 PMC: 10169321. DOI: 10.1016/j.jcvp.2023.100151.

Knowledge Mapping of Drug Repositioning's Theme and Development.

Lang X, Liu J, Zhang G, Feng X, Dan W Drug Des Devel Ther. 2023; 17:1157-1174.

PMID: 37096060 PMC: 10122475. DOI: 10.2147/DDDT.S405906.

References

Dyall J, Coleman C, Hart B, Venkataraman T, Holbrook M, Kindrachuk J . Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014; 58(8):4885-93. PMC: 4136000. DOI: 10.1128/AAC.03036-14. View

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Jiang Y, Han Z, Wang Y, Hao W . Depletion of SIRT7 sensitizes human non-small cell lung cancer cells to gemcitabine therapy by inhibiting autophagy. Biochem Biophys Res Commun. 2018; 506(1):266-271. DOI: 10.1016/j.bbrc.2018.10.089. View

Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

Lobo-Galo N, Terrazas-Lopez M, Martinez-Martinez A, Diaz-Sanchez A . FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. J Biomol Struct Dyn. 2020; 39(9):3419-3427. PMC: 7232886. DOI: 10.1080/07391102.2020.1764393. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Andersen P, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjoras M . Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis. 2020; 93:268-276. PMC: 7128205. DOI: 10.1016/j.ijid.2020.02.018. View

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

Weston S, Coleman C, Haupt R, Logue J, Matthews K, Li Y . Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV . J Virol. 2020; 94(21). PMC: 7565640. DOI: 10.1128/JVI.01218-20. View

10.

Dai W, Zhang B, Jiang X, Su H, Li J, Zhao Y . Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020; 368(6497):1331-1335. PMC: 7179937. DOI: 10.1126/science.abb4489. View

11.

Cao J, Forrest J, Zhang X . A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res. 2014; 114:1-10. PMC: 7113785. DOI: 10.1016/j.antiviral.2014.11.010. View

12.

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

13.

Osborn M . Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2009; 5:789-98. PMC: 2762437. DOI: 10.2147/tcrm.s5318. View

14.

Menendez C, Chollet A, Rodriguez F, Inard C, Pasca M, Lherbet C . Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents. Eur J Med Chem. 2012; 52:275-83. DOI: 10.1016/j.ejmech.2012.03.029. View

15.

Weiss S, Navas-Martin S . Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69(4):635-64. PMC: 1306801. DOI: 10.1128/MMBR.69.4.635-664.2005. View

16.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

17.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

18.

Jiang F, Deng L, Zhang L, Cai Y, Cheung C, Xia Z . Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020; 35(5):1545-1549. PMC: 7088708. DOI: 10.1007/s11606-020-05762-w. View

19.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

20.

Taccone F, Gorham J, Vincent J . Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020; 8(6):539-541. PMC: 7159849. DOI: 10.1016/S2213-2600(20)30172-7. View